Intuitive Surgical stock gains 3.08 percent ahead of Q3 results

Published on 10/05/2026 at 19:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock was trading at USD 404.02 on October 5, 2026, as Europe-related approvals lifted the shares. Q2 revenue rose 18.4 percent to USD 2.89 billion.

Pop-Art-Comic zeigt Operationsroboter mit mehreren Armen und Chirurgen an der Konsole — Farbenfrohe Pop-Art-Comic-Szene aus dem Operationssaal illustriert Intuitive Surgical Inc. (US46120E6023) mit dynamischer Chirurgie-Roboter-Darstellung, Illustration mit AI erstellt.

Intuitive Surgical (ISIN US46120E6023) was trading at USD 404.02 on Nasdaq on October 5, 2026, up 3.08 percent from the prior close. TradingKey linked the move to European regulatory progress, clinical milestones and positioning ahead of the third-quarter report. The combination puts procedure growth and platform adoption back at the center of the stock story.

Q2 revenue rose 18.4 percent

Intuitive Surgical reported second-quarter 2026 revenue of USD 2.89 billion, up 18.4 percent from the same period a year earlier. According to MarketBeat, adjusted EPS was USD 2.80 against a USD 2.48 consensus estimate, a USD 0.32 beat.

The quarterly result also showed why recurring activity matters more than system placements alone. Yahoo Finance reported that total procedures increased 16 percent, da Vinci procedures rose 15 percent and Ion procedures advanced 36 percent. Recurring revenue reached USD 2.47 billion, equal to 85 percent of total revenue.

October 20 brings the next test

Yahoo Finance reported that Intuitive Surgical is scheduled to release third-quarter 2026 results after the market close on October 20, 2026. The market will be looking for evidence that the slower US procedure trend is stabilizing, particularly after management maintained full-year da Vinci procedure growth guidance of 13.5 percent to 15.5 percent.

The same outlook also leaves a second issue for the earnings call. Intuitive plans to extend the useful life of selected instruments in the first half of 2027, lowering customer cost per procedure while potentially reducing revenue per procedure. Management said it would provide additional quantification on the next earnings call, making the October report a test of both adoption and economics.

Consensus stays above the stock

Analyst expectations remain higher than the current quote. Markets Insider reported on October 2 that RBC Capital maintained a Buy rating with a USD 575.00 price target on October 1. The report also put the consensus at Strong Buy with an average target of USD 489.95.

At USD 404.02, that average target lies 21.27 percent above the Nasdaq price. The gap gives the coming results a clear role: continued procedure growth could support the valuation, while weaker US demand or lower instrument revenue per procedure would challenge the premium.

Stock trades below its yearly high

Intuitive Surgical was trading at USD 404.02 on Nasdaq on October 5, 2026 at 1:00 p.m. ET. Its market capitalization was USD 142.7 billion, while the 52-week range stood at USD 328.57 to USD 603.88 and volume reached 625,138 shares.